UCB Commits $2 Billion to Georgia Biologics Campus, Expanding U.S. Manufacturing Footprint
Event summary
- UCB dedicated a 79-acre site in Gwinnett County, Georgia, for a new $2 billion biologics manufacturing campus on October 9, 2026.
- The 460,000-square-foot facility will create 330 permanent jobs and support over 1,000 construction jobs, with an expected $5 billion economic impact.
- The campus will leverage AI, automation, and advanced manufacturing technologies to produce complex biologic medicines.
- UCB has maintained a U.S. presence for nearly a century, with over 2,000 employees across research, development, and commercial operations.
The big picture
UCB's investment underscores the growing trend of biopharmaceutical companies expanding domestic manufacturing capabilities to enhance supply chain resilience and meet increasing demand for complex biologic medicines. The $2 billion commitment also highlights Georgia's emergence as a life sciences hub, attracting significant investments due to its skilled workforce and robust infrastructure. This strategic move aligns with broader industry shifts towards localized production and digital-first manufacturing approaches.
What we're watching
- Execution Risk
- The pace at which UCB can complete construction and commence production will determine the timeline for realizing the expected economic benefits.
- Workforce Development
- Whether UCB's partnerships with local universities and workforce development organizations can successfully cultivate the necessary biomanufacturing talent.
- Supply Chain Resilience
- How the new campus will integrate into UCB's existing U.S. patient value chain and enhance its supply chain resilience.
